Abstract
Although recombinant human erythropoietin products are available for anemia of CKD in cats, the problem is the production of anti-erythropoietin antibodies with the subsequent development of aplastic anemia. Recently, it has been suggested that the disorder of iron metabolism is associated with a resistance to erythrocyte-stimulating analogues. In particular, hepcidin is considered as the central regulator of systemic iron homeostasis and mediator of anemia of inflammation. In this report, because it is important to reveal the iron status of anemia of CKD in cats in order to overcome the ESA resistance, it is detailed as follows.
